Absorption and disposition of scutellarin in rats: A pharmacokinetic explanation for the high exposure of its isomeric metabolite

Drug Metabolism and Disposition

Volumn 39, Issue 11, 2011, Pages 2034-2044

  Gao, Chunying ^a   Chen, Xiaoyan ^a   Zhong, Dafang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; SCUTELLAREIN 6 O GLUCURONIDE; SCUTELLARIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG UPTAKE; DRUG URINE LEVEL; INTESTINE ABSORPTION; INTESTINE WALL; LIVER CELL; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; RAT; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; APIGENIN; BILE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL LINE, TUMOR; GLUCURONIC ACIDS; GLUCURONIDES; HEPATOCYTES; HUMANS; HYDROLYSIS; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; SPLANCHNIC CIRCULATION;

RATTUS;

EID: 80054742937     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040550     Document Type: Article

References (31)

1. Abe K, Inoue O, and Yumioka E (1990) Biliary excretion of metabolites of baicalin and baicalein in rats. Chem Pharm Bull 38:209-211.
2. Akao T, Kawabata K, Yanagisawa E, Ishihara K, Mizuhara Y, Wakui Y, Sakashita Y, and Kobashi K (2000) Baicalin, the predominant flavone glucuronide of Scutellariae Radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J Pharm Pharmacol 52:1563-1568. (Pubitemid 32058657)
3. Cao F, Zhang H, Guo J, and Ping Q (2008) Mrp2-related efflux of scutellarin in the intestinal absorption in rats. Pharmazie 63:75-80. (Pubitemid 351155209)
4. Chen X, Cui L, Duan X, Ma B, and Zhong D (2006) Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration. Drug Metab Dispos 34:1345-1352. (Pubitemid 44079875)
5. Ge Q, Zhou Z, Zhi X, Ma L, and Chen X (2003) Pharmacokinetics and absolute bioavailability of breviscapine in Beagle dogs. Chin J Pharmaceuticals 34:618-620.
6. George J (2008) Elevated serum beta-glucuronidase reflects hepatic lysosomal fragility following toxic liver injury in rats. Biochem Cell Biol 86:235-243.
7. Hao X, Cheng G, Yu JE, He Y, An F, Sun J, and Cui F (2005) Study on the role of hepatic first-pass elimination in the low oral bioavailability of scutellarin in rats. Pharmazie 60:477-478. (Pubitemid 40966309)
8. Hassimotto NM, Genovese MI, and Lajolo FM (2008) Absorption and metabolism of cyanidin-3-glucoside and cyanidin-3-rutinoside extracted from wild mulberry (Morus nigra L.) in rats. Nutr Res 28:198-207. (Pubitemid 351459613)
9. Hong H and Liu GQ (2004) Protection against hydrogen peroxide-induced cytotoxicity in PC12 cells by scutellarin. Life Sci 74:2959-2973. (Pubitemid 38402293)
10. Huang JM, Weng WY, Huang XB, Ji YH, and Chen E (2005) Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats. Eur J Drug Metab Pharmacokinet 30:165-170. (Pubitemid 41499257)
11. King CD, Rios GR, Green MD, and Tephly TR (2000) UDP- glucuronosyltransferases. Curr Drug Metab 1:143-161.
12. Liu Q, Shi Y, Wang Y, Lu J, Cong W, Luo G, and Wang Y (2009) Metabolism profile of scutellarin in urine following oral administration to rats by ultra performance liquid chromatography coupled to time-of-flight mass spectrometry. Talanta 80:84-91.
13. Taiming L and Xuehua J (2006) Investigation of the absorption mechanisms of baicalin and baicalein in rats. J Pharm Sci 95:1326-1333. (Pubitemid 43874446)
14. Lucier GW, McDaniel OS, and Matthews HB (1971) Microsomal rat liver UDP glucuronyl-transferase: effects of piperonyl butoxide and other factors on enzyme activity. Arch Biochem Biophys 145:520-530.
15. Luo P, Zhang Z, Yi T, Zhang H, Liu X, and Mo Z (2008) Anti-inflammatory activity of the extracts and fractions from Erigeron multiradiatus through bioassay-guided procedures. J Ethnopharmacol 119:232-237.
16. McConnell EL, Basit AW, and Murdan S (2008) Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 60:63-70.
17. Miyazawa T, Nakagawa K, Kudo M, Muraishi K, and Someya K (1999) Direct intestinal absorption of red fruit anthocyanins, cyanidin-3-glucoside and cyanidin-3,5-diglucoside, into rats and humans. J Agric Food Chem 47:1083-1091. (Pubitemid 29182967)
18. O'Leary KA, Day AJ, Needs PW, Sly WS, O'Brien NM, and Williamson G (2001) Flavonoid glucuronides are substrates for human liver β-glucuronidase. FEBS Lett 503:103-106. (Pubitemid 32769964)
19. Pan Z, Feng T, Shan L, Cai B, Chu W, Niu H, Lu Y, and Yang B (2008) Scutellarin-induced endothelium-independent relaxation in rat aorta. Phytother Res 22:1428-1433. (Pubitemid 352789608)
20. Rao GS, Rao ML, and Breuer H (1970) Studies on a testosterone glucuronyltransferase from the cytosol fraction of human liver. Biochem J 119:635-642.
21. Setchell KD, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE, Kirschner AS, and Heubi JE (2002) Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 76:447-453. (Pubitemid 34804071)
22. Waterborg J and Matthews H (1996) The Lowry method for protein quantitation, in The Protein Protocols Handbook (Walker JM ed) pp 7-9, Humana Press, Totowa, NJ.
23. Xia H, Zhu S, Liang J, Chen L, Di X, and Qiu F (2009) Identification of metabolites in plasma, bile, urine, and faeces samples of rats after ig administered with breviscapine. Chin Tradit Herbal Drugs 40:1362-1366.
24. Xing J, Chen X, Sun Y, Luan Y, and Zhong D (2005a) Interaction of baicalin and baicalein with antibiotics in the gastrointestinal tract. J Pharm Pharmacol 57:743-750. (Pubitemid 40694882)
25. Xing J, Chen X, and Zhong D (2005b) Absorption and enterohepatic circulation of baicalin in rats. Life Sci 78:140-146. (Pubitemid 41560966)
26. Xing J, Chen X, and Zhong D (2005c) Stability of baicalin in biological fluids in vitro. J Pharmaceut Biomed 39:593-600. (Pubitemid 41196068)
27. You H, Zhang H, Dong Y, Chen S, Wang M, Dong W, and Xing J (2010) Absorption and transportation characteristics of scutellarin and scutellarein across Caco-2 monolayer model. Chin J Integr Med 8:863.
28. Zhang L, Lin G, Kovács B, Jani M, Krajcsi P, and Zuo Z (2007a) Mechanistic study on the intestinal absorption and disposition of baicalein. Eur J Pharm Sci 31:221-231. (Pubitemid 46818982)
29. Zhang L, Lin G, and Zuo Z (2007b) Involvement of UDP- glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein. Pharmaceut Res 24:81-89. (Pubitemid 44902573)
30. Zhong D, Yang B, Chen X, Li K, and Xu J (2003) Determination of scutellarin in rat plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 796: 439-444. (Pubitemid 37329687)
31. Zhu JT, Choi RC, Li J, Xie HQ, Bi CW, Cheung AW, Dong TT, Jiang ZY, Chen JJ, and Tsim KW (2009) Estrogenic and neuroprotective properties of scutellarin from Erigeron breviscapus: a drug against postmenopausal symptoms and Alzheimer's disease. Planta Med 75:1489-1493.